ID   DR177
AC   CVCL_A1YN
DR   Wikidata; Q105506769
RX   PubMed=22257080;
RX   PubMed=24443327;
CC   Population: Caucasian.
CC   Doubling time: 32.9 hours (PubMed=24443327).
CC   Derived from site: In situ; Brain; UBERON=UBERON_0000955.
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   68Y
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 29-06-23; Version: 4
//
RX   PubMed=22257080; DOI=10.1111/j.1750-3639.2012.00566.x; PMCID=PMC8057648;
RA   Raso A., Vecchio D., Cappelli E., Ropolo M., Poggi A., Nozza P.,
RA   Biassoni R., Mascelli S., Capra V., Kalfas F., Severi P., Frosina G.;
RT   "Characterization of glioma stem cells through multiple stem cell
RT   markers and their specific sensitization to double-strand
RT   break-inducing agents by pharmacological inhibition of ataxia
RT   telangiectasia mutated protein.";
RL   Brain Pathol. 22:677-688(2012).
//
RX   PubMed=24443327; DOI=10.1002/ijc.28680;
RA   Vecchio D., Daga A., Carra E., Marubbi D., Baio G., Neumaier C.E.,
RA   Vagge S., Corvo R., Brisigotti M.P., Ravetti J.L., Zunino A.,
RA   Poggi A., Mascelli S., Raso A., Frosina G.;
RT   "Predictability, efficacy and safety of radiosensitization of
RT   glioblastoma-initiating cells by the ATM inhibitor KU-60019.";
RL   Int. J. Cancer 135:479-491(2014).
//